Title:
SULFONYLUREA COMPOUND
Document Type and Number:
WIPO Patent Application WO/2023/116812
Kind Code:
A1
Abstract:
The present disclosure provides a sulfonylurea compound. Specifically, provided are a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a use thereof in preparation of a drug for treating diseases associated with NLRP3 activity. Groups in formula (I) are as defined in the description.
Inventors:
ZHANG LIMING (CN)
HAO XIN (CN)
LYU YUE (CN)
SONG YUNPENG (CN)
HAO XIN (CN)
LYU YUE (CN)
SONG YUNPENG (CN)
Application Number:
PCT/CN2022/140921
Publication Date:
June 29, 2023
Filing Date:
December 22, 2022
Export Citation:
Assignee:
REISTONE BIOPHARMA COMPANY LTD (CN)
International Classes:
C07D207/333; A61K31/40; A61P1/00; A61P1/16; C07D231/18
Domestic Patent References:
| WO2021009566A1 | 2021-01-21 |
Foreign References:
| CN113056451A | 2021-06-29 | |||
| CN110366549A | 2019-10-22 | |||
| CN110914256A | 2020-03-24 | |||
| CN111093773A | 2020-05-01 | |||
| US20200270227A1 | 2020-08-27 |
Attorney, Agent or Firm:
GE CHENG & CO.,LTD. (CN)
Download PDF:
Previous Patent: SHORT PEPTIDE COMPOUND CONTAINING β-AMINOKETONE AND USE THEREOF
Next Patent: ANTI-TNFR2 ANTIBODIES AND USES THEREOF
Next Patent: ANTI-TNFR2 ANTIBODIES AND USES THEREOF